問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital

Division of Thoracic Medicine

更新時間:2025-08-20

張芝榕
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

7Cases

2025-11-01 - 2030-12-31

Phase II

Active
A phase 2b/3, randomized, double-blind, placebo-controlled, multicenter trial was conducted to investigate the efficacy and safety of lunsekimig in adult subjects with poorly controlled chronic obstructive pulmonary disease (COPD) of the eosinophilic leukocytosis phenotype.
  • Condition/Disease

    The efficacy of lunsekimig was assessed by measuring the annualized incidence of moderate to severe COPD exacerbations.

  • Test Drug

    Lunsekimig/ SAR443765

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2024-04-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2023-06-01 - 2025-06-23

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2024-06-20 - 2027-09-01

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2027-10-01

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-10-16 - 2027-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2024-09-16 - 2027-09-24

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites